Biocon
-
Biocon and Pfizer enter into global commercialization agreement
Biocon and Pfizer entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of insulin and insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Pfizer will have excl…
Biocon | 12 January 2011
-
Amylin and Biocon Sign Agreement for Peptide Hybrid Development
Amylin Pharmaceuticals and Biocon have entered into an exclusive agreement to jointly develop, commercialize and manufacture a peptide therapeutic for the potential treatment of diabetes. The companies will collaborate to develop the therapeutic pote…
Biocon | 24 September 2009
-
Biocon and Mylan Collaborate to Enter Global Generic Biologics Market
Biocon has executed a definitive agreement with Mylan for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace. The companies will…
Biocon | 03 July 2009
-
Pall Introduces Biocontainers
Pall Life Sciences has introduced its line of Allegro3D biocontainers. The product is developed for upstream production and downstream purification applications in the production of biotherapeutic molecules. These applications include cell culture me…
Biocon | 23 December 2008
-
Biocon Acquires 70% Stake In German Pharmaceutical Company
Indian Biotechnology major, Biocon announced that it has reached agreement to acquire a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 million ($43.7 million). This will enable the marketing and distribution…
Biocon | 21 February 2008
-
India’s Biocon's Syngene Partners With Bristol-Myers Squibb In Research
Biocon Limited, India’s premier biotechnology company said its subsidiary company Syngene has entered into a research partnership with Bristol-Myers Squibb. Biocon’s Syngene will provide research and development (R&D) services for discovery and e…
Biocon | 23 March 2007
